Kintara Therapeutics Inc. (NASDAQ: KTRA) stock fell -10.41% on Friday to $0.22 against a previous-day closing price of $0.25. With 5.22 million shares changed hands, the volume of the stock remained heavier than its average volume of 3.71 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $0.2400 whereas the lowest price it dropped to was $0.2030. The 52-week range on KTRA shows that it touched its highest point at $1.65 and its lowest point at $0.14 during that stretch. It currently has a 1-year price target of $3.17. Beta for the stock currently stands at 1.08.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of KTRA was up-trending over the past week, with a rise of 12.45%, but this was down by -8.04% over a month. Three-month performance dropped to -18.46% while six-month performance fell -50.67%. The stock lost -85.17% in the past year, while it has lost -56.96% so far this year. A look at the trailing 12-month EPS for KTRA yields -0.68 with Next year EPS estimates of 0.03. For the next quarter, that number is -0.03. This implies an EPS growth rate of -83.30% for this year and 37.50% for next year.
Float and Shares Shorts:
At present, 49.13 million KTRA shares are outstanding with a float of 44.79 million shares on hand for trading. On Jul 14, 2022, short shares totaled 0.38 million, which was 0.59% higher than short shares on Jun 14, 2022. In addition to Mr. Robert E. Hoffman CPA, CPA as the firm’s Pres, CEO & Chairman, Mr. Scott Praill B.Sc., C.P.A., CA, CPA, BSc serves as its CFO & Sec.
Through their ownership of 5.75% of KTRA’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 3.02% of KTRA, in contrast to 2.28% held by mutual funds. Shares owned by individuals account for 0.86%. As the largest shareholder in KTRA with 2.14% of the stake, The Vanguard Group, Inc. holds 1,403,939 shares worth 1,403,939. A second-largest stockholder of KTRA, Nantahala Capital Management LLC, holds 663,279 shares, controlling over 1.01% of the firm’s shares. Geode Capital Management LLC is the third largest shareholder in KTRA, holding 568,419 shares or 0.87% stake. With a 1.57% stake in KTRA, the Vanguard Total Stock Market Index is the largest stakeholder. A total of 1,026,487 shares are owned by the mutual fund manager. The Vanguard Extended Market Index Fu, which owns about 0.58% of KTRA stock, is the second-largest Mutual Fund holder. It holds 377,452 shares valued at 0.1 million. Fidelity Comwlth. Tr. – Nasdaq Co holds 0.36% of the stake in KTRA, owning 234,221 shares worth 65113.0.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for KTRA since 1 analysts follow the stock currently. There are 0 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 1 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With KTRA analysts setting a high price target of $3.00 and a low target of $3.00, the average target price over the next 12 months is $3.00. Based on these targets, KTRA could surge 1263.64% to reach the target high and rise by 1263.64% to reach the target low. Reaching the average price target will result in a growth of 1263.64% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. KTRA will report FY 2022 earnings on 08/30/2023. Analysts have provided yearly estimates in a range of -$0.42 being high and -$0.42 being low. For KTRA, this leads to a yearly average estimate of -$0.42. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Kintara Therapeutics Inc. surprised analysts by -$0.00 when it reported -$0.11 EPS against a consensus estimate of -$0.11. The surprise factor in the prior quarter was $0.05. Based on analyst estimates, the high estimate for the next quarter is -$0.02 and the low estimate is -$0.02. The average estimate for the next quarter is thus -$0.02.
Summary of Insider Activity:
Insiders traded KTRA stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 5 while that of sell transactions has remained unmoved to 0 over the past year. The total number of shares bought during that period was 136,700 while 0 shares were sold.